iShares US Healthcare Providers

CVS Health Reaffirms Commitment to Military Community, Plans $292M Investment in 2025

Deutsche Bank Cuts Cigna Group Price Target to $302 from $303

Trump Portfolio Precisely Trades UnitedHealth Before Medicare Policy Reversal

Gamco Investors Reduces CVS Health Stake by 11.6% and Sells Nearly 15,000 Shares

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Humana Secures $1.5 Billion Financing Agreement to Issue Senior Notes

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

JPMorgan cuts HCA Healthcare price target to $490

Barclays Offers Structured Notes Linked to UnitedHealth Group Stock

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

North Dakota Investment Board Increases CVS Holdings as Q1 Earnings Beat Expectations

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

CVS Health Joins CNCF as Platinum Member to Optimize Tech Architecture

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

UnitedHealth's Optum Rx Introduces New Pharmacy Care Model for Transparency

UnitedHealth Group to Host UHC Medicare Sales Virtual Job Fair

DNB Asset Management Increases CVS Stake by 17.6%, Analysts Upgrade to Buy

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

Micware

BiomX

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

Pinned News

置顶新闻

Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

IBBQ

SBIO

LABU

ARKG

Bristol-Myers Squibb Co. (NYSE:BMY) announced a strategic partnership with Anthropic to enhance drug discovery using AI, leading to a slight increase in shares. This collaboration aims to integrate AI into various workflows, building on three years of AI investment. Additionally, a partnership with Tempus AI Inc. focuses on improving clinical trial design and success rates in oncology and neuroscience. BMY shares rose 0.12% to $58.38 on Wednesday.

benzinga_article

Bristol Myers Squibb

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VG Health

Ark Genomic Revolution ETF

iShares Biotechnology ETF

iShares Global Healthcare

Tempus AI

Invesco S&P Ultra Dividend Revenue ETF

VanEck Pharmaceutical ETF

iShares US Pharma

Intuit

Bristol-Myers Squibb Company

AMST

Amesite Inc. (AMST) stock surged 10.92% on Wednesday, following a significant 2,700-patient enterprise win for its NurseMagic AI platform and improved Q3 financial results. The company reported a narrower loss of 15 cents per share and revenue growth to $83,332. The stock has risen 147% since Monday, driven by the contract aimed at streamlining clinical workflows in the healthcare sector.

Amesite

SPDR S&P Health

S&P 500

Why Amesite Stock Is Surging On Wednesday?

ALHC

Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity

Barchart Option

Alignment Healthcare

Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity

OPCH

The Law Offices of Frank R. Cruz is investigating Option Care Health, Inc. (NASDAQ: OPCH) for potential violations of federal securities laws. Following the release of disappointing Q1 2026 financial results, which included a revenue miss and lowered full-year guidance, OPCH's stock fell 24.3%. Shareholders who lost money are encouraged to contact the law firm for potential claims.

MorningStar

Option Care Health

Health Care Select Sector SPDR

Securities Fraud Investigation Into Option Care Health, Inc. (OPCH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

UNHG

Mizuho has raised its price target for UnitedHealth Group (NYSE:UNH) from $410.00 to $440.00, maintaining an 'outperform' rating. This new target suggests a potential upside of 13.06% from the current price. Other brokerages have also increased their targets, with an average price target of $385.39 and a consensus rating of 'Moderate Buy'. UnitedHealth Group reported strong quarterly earnings, exceeding estimates with $7.23 EPS and $111.65 billion in revenue.

Market Beat

Unitedhealth

Leverage Shares 2X Long UNH Daily ETF

Mizuho Financial Group, Inc.

Mizuho Financial

Berkshire Hathaway

Berkshire Hathaway B

Wells Fargo

JPMorgan Chase

Morgan Stanley

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Mizuho Raises UnitedHealth Group (NYSE:UNH) Price Target to $440.00

AVNS

Two health care stocks, Avanos Medical Inc (AVNS) and Agilon Health Inc (AGL), are showing signs of being overbought, with RSI values of 87.8 and 86.6, respectively. AVNS has surged 127% over the past six months, while AGL has skyrocketed 212% in the last month. Both companies reported better-than-expected earnings and raised sales guidance, but their high RSI indicates potential price corrections ahead.

Avanos Medical

agilon health

Top 2 Health Care Stocks That May Plunge This Month

HIMS

HIMZ

HIMY

Hims & Hers Health CFO Oluyemi Okupe sold 7,950 shares at $23.64 each, totaling $187,938, reducing his holdings by 2.93%. Post-sale, he owns 262,954 shares valued at approximately $6.22 million. This transaction was part of a pre-arranged trading plan and disclosed to the SEC. The company's stock has seen fluctuations, with recent earnings missing estimates and a market cap of $5.12 billion.

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Defiance Leveraged Long +Income HIMS ETF

Eli Lilly

Novo Nordisk AS

Bank of America

UBS Group AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Universal Health Services Inc. Cl B (UHS) shares fell 1.67% to $166.45 on Tuesday, underperforming against competitors as the S&P 500 and Dow Jones also declined. UHS is currently 32.43% below its 52-week high of $246.33. In contrast, Select Medical Holdings Corp. rose 0.18%, while Community Health Systems remained unchanged, and Pediatrix Medical Group increased by 1.63%. Trading volume was below the 50-day average.

MarketWatch Automated

Universal Health Service-B

Dow Jones Industrial Average

Select Medical

Community Health

Pediatrix Medical

Universal Health Services Inc. Cl B Stock Underperforms Tuesday When Compared To Competitors

ResMed Inc. (RMD) shares rose 1.78% to $207.78 on Tuesday, outperforming a declining market where the S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. This marks the second consecutive day of gains for ResMed, although it remains 29.28% below its 52-week high of $293.81 reached on August 22nd. Trading volume was 1.4 million, surpassing the 50-day average of 1.2 million.

Resmed

SPDR S&P Health Equip

iShares US Medical Devices

Factset Research

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Elevance Health Inc. (ELV) shares rose 2.08% to $402.27 on a weak trading day for the market, outperforming competitors like UnitedHealth Group (UNH) which fell 0.48%. The stock is 2.59% below its 52-week high of $412.96. Trading volume was 1.6 million, below the 50-day average of 1.8 million.

Elevance Health

Cigna

Humana

Elevance Health Inc. Stock Outperforms Competitors On Strong Trading Day

MGRX

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

Mangoceuticals

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

iShares US Healthcare Providers(IHF.US)

Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

Why Amesite Stock Is Surging On Wednesday?

Medicare Advantage Company Alignment Healthcare Shows Huge, Unusual Call Option Activity

Securities Fraud Investigation Into Option Care Health, Inc. (OPCH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Mizuho Raises UnitedHealth Group (NYSE:UNH) Price Target to $440.00

Top 2 Health Care Stocks That May Plunge This Month

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Universal Health Services Inc. Cl B Stock Underperforms Tuesday When Compared To Competitors

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Elevance Health Inc. Stock Outperforms Competitors On Strong Trading Day

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary